http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002058661-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2001-09-07^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4872d72b6846cf386ad3dbaa45fe387a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e17af2305616922b9994c9e8c204e5d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_046f201363bbfc820bcc127192e976e9 |
| publicationDate | 2002-05-16^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002058661-A1 |
| titleOfInvention | Bioavailability 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors |
| abstract | The present invention relates to novel 3-hetero-arylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which have improved hydrosolubility and which are expected to modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer. |
| priorityDate | 1997-06-20^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 1000 of 1194.
| Next Page | Last Page |